OVARIAN CANCER

Resistance of ovarian cancer treatment strategy Tumor resistance of the tumor cells to anticancer drugs that showed no reaction of the state of ovarian cancer chemotherapy failure is the ...

Taxol combined platinum treatment of ovarian cancer care "Nursing Care of Patients Treated With Combination Oophoroma of Taxolr and Platinum" ovarian cancer in the female genital cancer i...

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Cleveland-based American University Hospital of ovarian cancer that statins gemcitabine and cisplatin have synergies, gemcitabine and cisplatin combination on statin drugs cisplatin and more uncontrollable drug uncontrollable peritoneal ovarian cancer and the treatment of cancer was evaluated. Methods: a 21-day course of treatment, in 1-8 days intravenous cisplatin (30 mg/m2) after injection of gemcitabine Ting (750 mg/m2), 30 minutes after injection. If the eighth day of the neutrophil cell number <1000/mm3 terms of the number of platelets or <75,000 / mm3, eight days of injection canceled. If there Neutropenia of sepsis and severe thrombocytopenia disease, gradually reduce the dose of statins gemcitabine (600,400,300 mg/m2). Results: 36 pairs participate in the study drugs cisplatin and paclitaxel resistance in the 35 patients with a treatment evaluation of 15 patients reaction (42.9%), some 11 clinical response, four full response. A response to treatment of patients, the median duration of response was 11 months, all patients with disease progression in the median time interval of 6 months (1-14 months), the median survival time was 12 months. The results show that statins gemcitabine and cisplatin in the treatment of cisplatin-resistant patients with a positive role (MD intact. 2003 Jan; 88 (1) LA-21).

California City of Hope National Medical Center to detect recurrence of ovarian cancer patients received 26 hours of continuous cyclosporin A (CSA) and a fixed dose of carboplatin (CBDCA) in the treatment of the reaction and the CSA right Assays metabolism. Experimental Design: In vitro using the A2780 platinum-resistant cells through cloning analysis of the CAS continued on the reversal of Anticancer Drug Resistance; In Phase II clinical study, the patients once every three weeks Assays (AUC) and CSA treatment of patients with the CSA and Sensitivity pharmacokinetics. Results: CSA pre-incubation platinum resistance reversal Assays A2780 cell resistance associated with the dose and time. 23 patients received 58 courses of Sensitivity / CSA treatment, the treatment of some of the reaction is one cases in a stable condition with eight cases. Toxicity and Phase I clinical trial results similar to a bone marrow suppression, nausea, vomiting and headache. CSA median reperfusion of the 1253 / - 400 μ g / ml. Pharmacokinetic studies show that the CSA not increase Assays AUC (area under the concentration-time curve) (Cancer Chemother Pharmacol. 2004 Oct; 54 (4) 283-294-9. Epub 2004 Jun 4).

Japan's Niigata University School of Medicine tested hydrochloride irinotecan (CPT-11) and mitomycin C (MMC) in the treatment of platinum-drug program uncontrollable patients with ovarian cancer treatment. 1,15,29 patients in the days to CPT-11 (140 mg/m2) and MMC (7 mg/m2) treatment, if the disease continues to deteriorate, unacceptable toxicity or voluntarily give up, to stop treatment. Results of 13 patients received 61 courses of CPT-11/MMC. The main toxicity was Neutropenia, easier to reverse. More moderate non-hematologic toxicity. Treatment of 13 patients, four cases of treatment response (1CR, 3PRs). A response to treatment of patients, the median response time of 30 continuous weeks. Again development of the cancer-time for 24 weeks, with a median survival time of 36 weeks. The pre-clinical study showed that CPT-11/MMC right combination of platinum drugs uncontrollable ovarian cancer patients have a positive effect (Am J Clin Oncol. 2004 Oct; 27 (5) :461-4).

Treatment of ovarian cancer chemotherapy new program Researchers reported that the joint use of both cisplatin and paclitaxel chemotherapy drug for ovarian cancer achieved better clinical remis...

Intraperitoneal chemotherapy should be first-line therapy in ovarian cancer A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understan...

Cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer drug side effects Whitney physicians that cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer treatment should become the new standard. Ca...

Recurrent ovarian cancer chemotherapy new method - conventional chemotherapy drug efficacy forecast molecular targeted chemotherapy Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates gene...

The FDA approved a new therapy for ovarian cancer paclitaxel (Taxol) therapy Abstract: The FDA approved a new treatment of advanced ovarian cancer on the first line of the short-term treatment programs, in the treatm...

Taxol and carboplatin Joint effective treatment of advanced ovarian cancer According to an obstetrics and gynecology oncology groups (GOG) study said that the smaller Phase III epithelial ovarian cancer patients, ca...

Diagnostic Classification

Experience with ovarian cancer

Tags: anti, cancer, carboplatin, cases, cell, cells, chemotherapy, cisplatin, clinical, csa, days, dose, drug, drugs, eat, head, injection, intravenous, method, ovarian, paclitaxel, patients, positive, rate, reduce, response, study, surgery, survival, therapy, time, toxicity, treatment